Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline

Abstract

Objective: The objectives of this double-blind study were to assess the tolerability and i.v. tyramine pressor response during combined treatment with moclobemide and selegiline.

Subjects: Two parallel groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.d. for 14 days. On Day 7, selegiline or moclobemide was added to the other treatment. IV tyramine pressor tests were conducted at baseline and at steady state during mono- and combined treatment.

Results: Treatment with moclobemide and selegiline alone was well tolerated, whereas combined treatment led to a slight increase in adverse events. Tyramine pressor sensitivity during moclobemide, selegiline and moclobemide + selegiline treatment was enhanced, on average, by 2.4-, 1.3- and 8.4-times, respectively.

Conclusion: Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Blackwell B, Marley E, Price J, Tylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and food-stuffs. Br J Psychiat 113:349–365.

  2. 2.

    Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297.

  3. 3.

    Houslay MD, Tipton KF, Youdim MBH (1971) Multiple forms of monoamine oxidase, fact and artifact. Life Sci 19:467–478.

  4. 4.

    Hasan F, McCrodden JM, Kennedy NP, Tipton KF (1988) The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm [Suppl] 26:1–9.

  5. 5.

    Illet KF, George CF, Davies DS (1980) The effect of monoamine oxidase inhibitors on first-pass metabolism of tyramine in dog intestine. Biochem Pharmacol 29:2551–2556.

  6. 6.

    Dollery CT, Brown MJ, Davies DS, Lewis PJ, Strolin-Benedetti M (1983) Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Clin Pharmacol Ther 34:651–662.

  7. 7.

    Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Manigilio D, Haefely WE (1988) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400–414.

  8. 8.

    Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology [Suppl] 106:6–14.

  9. 9.

    Fitton A, Faulds D, Goa KL (1992) Moclobemide:A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561–596.

  10. 10.

    Priest RG, Schmid-Burgk W (1994) Moclobemide in the treatment of depression. Rev Contemp Pharmacother 5:35–43.

  11. 11.

    Kom A, Da Prada M, Raffesberg W, Gasic S, Eichler HG (1988) Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11:17–23.

  12. 12.

    Kom A, Da Prada M, Raffesberg W, Allen S, Gasic S (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm [Suppl] 26:57–71.

  13. 13.

    Wijnands S, Chang PC, Blauw GJ, van den Krogt J, Gieschke R, Schoerlin M-P, van Brummelen P (1989) Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol 3:36–44.

  14. 14.

    Chrisp P, Mammen GJ, Sorkin ME (1991) Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1:228–248.

  15. 15.

    Youdim MBH, Da Prada M, Amrein R (1988) The cheese effect and new reversible MAO-A inhibitors. J Neural Transm [Suppl] 26:1–136.

  16. 16.

    Waldmeier PC, Felner AE (1978) Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 27:801–802.

  17. 17.

    Cummings JL (1992) Depression and Parkinson's disease. Am J Psychiat 149:443–454.

  18. 18.

    Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology 70:163–166.

  19. 19.

    Bieck PR, Antonin K-H (1988) Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8:237–245.

  20. 20.

    Guentert TW, Mayerson M (1994) Clinical-pharmacokinetic profile of moclobemide and its comparison with other MAO-inhibitors. Rev Contemp Pharmacother 5:19–34.

  21. 21.

    Bieck PR, Antonin KH, Schmidt E (1993) Clinical pharmacology of reversible monoamine oxidase-A inhibitors. Clin Neuropharmacol 16 [Suppl 2]:S34-S41.

  22. 22.

    Felner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28:995–1002.

  23. 23.

    Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 84 [Suppl 136]:44–59.

  24. 24.

    Gerlach M, Riederer P, Youdim M (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226:97–108.

  25. 25.

    Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86:432–437.

  26. 26.

    Schulz R, Antonin K-H, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR (1989) Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 46:528–536.

  27. 27.

    Neff NH, Yang HYT (1974) Another look of monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 14:2061–2074.

  28. 28.

    Heinonen EH, Anttila MI, Lammintausta RAS (1994) Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742–749.

  29. 29.

    Dingemanse J, Kneer J, Wallnöfer A, Kettler R, Zürcher G, Koulu M, Kom A (1995) Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol (in press).

  30. 30.

    Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH (1989) Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27:243–255.

  31. 31.

    Youdim MBH, Finberg JPM (1986) MAO type B inhibitors as adjunct to L-Dopa therapy. Adv Neurol 45:127–136.

  32. 32.

    Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacology 18:118–123.

  33. 33.

    Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolised to metamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542–544.

  34. 34.

    Somerset Pharmaceuticals Inc. (1995) Package insert Eldepryl®.

Download references

Author information

Correspondence to J. Dingemanse.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Korn, A., Wagner, B., Dingemanse, J. et al. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. Eur J Clin Pharmacol 49, 273–278 (1996). https://doi.org/10.1007/BF00226327

Download citation

Key words

  • Moclobemide
  • Selegiline
  • interaction
  • pharmacodyamics
  • tyramine